Brooklyn ImmunoTherapeutics Inc
BTX
Market Cap$1.26B
Close$
$0.44
92.5% downside
Current Fair Value
92.5% downsideOvervalued by 92.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.26 Billion |
|---|---|
| Enterprise Value | $1.26 Billion |
| Dividend Yield | $0.344 (5.84040747028862%) |
| Earnings per Share | $0.17 |
| Beta | 1.31 |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 35.61 |
|---|---|
| PEG | 9.48 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2101.27 |
| Enterprise Value to EBIT | -67.05 |
| Enterprise Value to Net Income | -28 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Brooklyn ImmunoTherapeutics Inc
2,018 employeesBrooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to a...